<DOC>
	<DOCNO>NCT00876512</DOCNO>
	<brief_summary>Dual antiplatelet therapy aspirin thienopyridines decrease rate stent thrombosis patient undergo percutaneous coronary intervention ( PCI ) . However , despite intensified antiplatelet treatment , patient undergo PCI develop thrombotic stent occlusion , suggest incomplete platelet inhibition due thienopyridine resistance . The present study design order clarify influence CYP2C19 genetic polymorphism several biomarkers platelet activation Japanese patient treated thienopyridines undergo elective PCI .</brief_summary>
	<brief_title>CYP2C19 Gene Alteration Thienopyridine Resistance Percutaneous Coronary Intervention Study</brief_title>
	<detailed_description>We enrol patient stable effort angina receive dual-antiplatelet therapy aspirin ( 100mg ) clopidogrel ( 75mg ) . We perform PCI 12-24 hour 300mg load dose clopidogrel , least 7 day 75mg clopidogrel treatment 300mg initial load dose . We examine platelet adhesiveness , plasma biomarkers platelet activation plasma VWF ADAMTS13 , CD40L , P-Selectin level , ADP-induced platelet aggregation use Light transmittance aggregometry ( LTA ) VerifyNow P2Y12 assay system patient . We also analyze CYP2C19 genetic polymorphism examine influence genetic variation several biomarkers platelet activation .</detailed_description>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>The stable effort angina patient More 20 year old Undergoing elective PCI treat aspirin clopidogrel Patients treat follow medical therapy ( ie . Warfarin , Steroid , thrombolytic drug , Ticlopidine , Sarpogrelate hydrochloride Cilostazol ) Patients follow disease ( deep vein thrombosis , atrial fibrillation , collagen disease , infection , liver renal dysfunction , malignant disease )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>thienopyridine resistance</keyword>
	<keyword>stable effort angina</keyword>
	<keyword>platelet activation</keyword>
	<keyword>ADAMTS13</keyword>
	<keyword>von Willebrand Factor</keyword>
</DOC>